TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12474117

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9787684

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol in frequent low doses (0.075 mg/kg every 30 minutes)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Addition of ipratropium bromide (250 micrograms)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Salbutamol in frequent low doses
Number of subjects: 298

Group type: COMPARATOR
Intervention: Salbutamol in hourly high doses (0.15 mg/kg every 60 minutes)
Number of subjects: 298
Study: 7625415

Group type: EXPERIMENTAL
Intervention: Sublingual estradiol‐17 beta (1 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 11
Study: 31930464

Group type: EXPERIMENTAL
Intervention: Risk identification tool for repeated intimate partner violence
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Perpetrator characteristics (unemployment, lack of regret, other violent criminal history, history of being beaten by a family member)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Victim characteristics (nonqualified education, predictions of future harm)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Relationship characteristics (different ethnicity, poor socioeconomic status, difference in incomes, living in a rental property, alcohol and drug use, unprocessed previous history of physical violence)
Number of subjects: 238
Study: 29898452

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention including regular monitoring and follow-up
Number of subjects: 865
Study: 26838934

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction with hamstring tendon graft (DB‐HT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Rectangular-tunnel single-bundle ACL reconstruction with patellar tendon graft (RTSB‐PT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: RTSB‐PT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DB‐HT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DB‐HT and RTSB‐PT
Number of subjects: 150
Study: 25404126

Group type: EXPERIMENTAL
Intervention: Intermittent Screening and Treatment (IST) with artemether-lumefantrine (AL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intermittent Preventive Treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Number of subjects: 30
Study: 23563134

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 21070457

Group type: EXPERIMENTAL
Intervention: 24‐mg/mL cohesive gel alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of 24‐mg/mL cohesive gel and onabotulinumtoxinA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 18271883

Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Number of subjects: 400
Study: 16564798

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 40
Study: 12548091

Group type: EXPERIMENTAL
Intervention: Intravenous epoprostenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous treprostinil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11007152

Group type: EXPERIMENTAL
Intervention: Self-deception scores in Study 1
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Self-deception scores in Study 2
Number of subjects: 220
Study: 9360182

Group type: EXPERIMENTAL
Intervention: Laminaria tents + 4 mg PGE2 gel
Number of subjects: 44

Group type: COMPARATOR
Intervention: PGE2 gel alone
Number of subjects: 44
Study: 1548570

Group type: EXPERIMENTAL
Intervention: Dapsone (100 mg p.o. daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (160 mg/800 mg p.o. daily)
Number of subjects: 86
Study: 4033132

Group type: EXPERIMENTAL
Intervention: 0.23 g/kg alcohol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.46 g/kg alcohol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.12 g/kg alcohol
Number of subjects: 11
Study: 30021578

Group type: EXPERIMENTAL
Intervention: PrevOP-PAP intervention (PrevOP-PAP-I)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Active control condition (PrevOP-PAP-CTRL)
Number of subjects: 240
Study: 29228919

Group type: EXPERIMENTAL
Intervention: CARe methodology training
Number of subjects: 263

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 263
Study: 26270552

Group type: EXPERIMENTAL
Intervention: Virtual reality modulation of self-agency (SA)
Number of subjects: 16
Study: 23963138

Group type: EXPERIMENTAL
Intervention: Hepatic resection
Number of subjects: 479

Group type: COMPARATOR
Intervention: Non-resected LLD patients
Number of subjects: 479

Group type: COMPARATOR
Intervention: Non-resected non-LLD patients
Number of subjects: 479
Study: 21406135

Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 0
Study: 18164094

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (0.15 U/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insulin lispro (0.15 U/kg)
Number of subjects: 18
Study: 17006711

Group type: EXPERIMENTAL
Intervention: 40%T (exercise at 40% of VO(2)max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60%T (exercise at 60% of VO(2)max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 70%T (exercise at 70% of VO(2)max)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ctr (control trial, no exercise)
Number of subjects: 10
Study: 12892384

Group type: EXPERIMENTAL
Intervention: Magnesium-orotate (3000 mg/day for 90 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10756246

Group type: EXPERIMENTAL
Intervention: Continuous infusion of contrast agent at different rates (3 rates, 10 or 20 minutes duration).
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bolus injection of contrast agent.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: End-systolic triggered imaging with MI of 1.5.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: End-diastolic triggered imaging.
Number of subjects: 19
Study: 8650428

Group type: EXPERIMENTAL
Intervention: Fish oil ethyl ester (Esapent, 5.1 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1501052

Group type: EXPERIMENTAL
Intervention: Intravenous IgM enriched immunoglobulin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study: 6593146

Group type: EXPERIMENTAL
Intervention: 0.2% neutral solution of sodium fluoride, 10 ml, rinsed every second week during the school year
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 29575737

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intraarticular glucocorticoid injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palpation-guided intraarticular glucocorticoid injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injecting clinically swollen joints without power Doppler (PD) activity on ultrasound
Number of subjects: 0
Study: 27561366

Group type: EXPERIMENTAL
Intervention: DTCP LUTS/BPH tool (Group B)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard treatment without DTCP (Group A)
Number of subjects: 278
Study: 25327602

Group type: EXPERIMENTAL
Intervention: 2.5 g of plant sterol esters a day (treatment group, n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 59
Study: 23535803

Group type: EXPERIMENTAL
Intervention: CKC exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: OKC exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 19758267

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 g MMF plus low-dose tacrolimus
Number of subjects: 0
Study: 19083666

Group type: EXPERIMENTAL
Intervention: Massage therapy (twice weekly from partners from 20 weeks gestation until the end of pregnancy)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 47
Study: 17217216

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400mg 3 times daily, as coated, sustained release tablets)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard drug group (multivitamin and local heat therapy)
Number of subjects: 29
Study: 14710168

Group type: EXPERIMENTAL
Intervention: Additional protein group (n=73) received 48.2 g/day additional protein.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-additional protein group (control).
Number of subjects: 148
Study: 11208675

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated BX Velocity stents (slow release)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated BX Velocity stents (fast release)
Number of subjects: 30
Study: 9258974

Group type: EXPERIMENTAL
Intervention: Oral administration of baclofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rectal administration of baclofen
Number of subjects: 0
Study: 8435362

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days + Verapamil (VPL) 480 mg orally one day before and during EPI
Number of subjects: 51

Group type: COMPARATOR
Intervention: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days without VPL
Number of subjects: 51
Study: 3579676

Group type: EXPERIMENTAL
Intervention: Interferon beta administered intrathecally (IT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30328305

Group type: EXPERIMENTAL
Intervention: Fiber post placed in the palatal canal (Group 4)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: No post placed (Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sound teeth with only metal crowns (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fiber post placed in both buccal and palatal canals (Group 5)
Number of subjects: 50
Study: 26970712

Group type: EXPERIMENTAL
Intervention: Androstadienone (ANDR)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Androstadienone (ANDR) during stress
Number of subjects: 46
Study: 24895301

Group type: EXPERIMENTAL
Intervention: Low-fluence Q-switched Nd:YAG laser (1,064 nm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fluence Q-switched alexandrite laser (755 nm)
Number of subjects: 20
Study: 23364390

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50 μg bid (FP100)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 μg bid (FP500)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 21
Study: 20385870

Group type: EXPERIMENTAL
Intervention: ST-246 250 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ST-246 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ST-246 800 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19112496

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone+artesunate (CD+A)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Amodiaquine+sulphadoxine-pyrimethamine (AQ+SP)
Number of subjects: 702
Study: 15821091

Group type: EXPERIMENTAL
Intervention: Nonverbal task examining understanding of true or false beliefs
Number of subjects: 0
Study: 12910336

Group type: EXPERIMENTAL
Intervention: Two-phased carers' intervention comprising family sessions followed by relatives' groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 10567284

Group type: EXPERIMENTAL
Intervention: Partial chordal preservation (posterior leaflet only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Complete chordal preservation (all chordal structures)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mitral valve repair (comparison group)
Number of subjects: 50
Study: 8921659

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (AquaCem, De Trey)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acrylic resin (Unite, Unitek Corp.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (AquaCem, De Trey) with cut groove base (DynaLock, Unitek)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acrylic resin (Unite, Unitek Corp.) with cut groove base (DynaLock, Unitek)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (AquaCem, De Trey) with meshed foil base (Unitwin, Unitek)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acrylic resin (Unite, Unitek Corp.) with meshed foil base (Unitwin, Unitek)
Number of subjects: 60
Study: 1832291

Group type: EXPERIMENTAL
Intervention: xipamide 20 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 6391928

Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg in the morning, placebo in the evening
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg in the evening, placebo in the morning
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg in the morning and 500 mg in the evening
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31654497

Group type: COMPARATOR
Intervention: Standard epithelium-off cross-linking (SCXL)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Accelerated epithelium-off cross-linking (ACXL)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Transepithelial epithelium-on cross-linking (TCXL)
Number of subjects: 271
Study: 31383465

Group type: EXPERIMENTAL
Intervention: Intraperitoneal antibiotic irrigation (polymyxin B, 500,000 units/L)
Number of subjects: 190

Group type: COMPARATOR
Intervention: 0.9% NaCl irrigation (saline)
Number of subjects: 190
Study: 29215302

Group type: EXPERIMENTAL
Intervention: Xing Qi Hua Ying Tang (XQHYT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hai Zao Yu Hu Tang (Control)
Number of subjects: 72
Study: 27881530

Group type: EXPERIMENTAL
Intervention: Menstrual cups
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Sanitary pads
Number of subjects: 751

Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 751
Study: 26149170

Group type: EXPERIMENTAL
Intervention: 1.25 mg of bevacizumab
Number of subjects: 246

Group type: COMPARATOR
Intervention: 0.5 mg of ranibizumab
Number of subjects: 246
Study: 22790501

Group type: EXPERIMENTAL
Intervention: Orthodontic manual toothbrush
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional manual toothbrush
Number of subjects: 64
Study: 20156032

Group type: EXPERIMENTAL
Intervention: P-OM3 4 g/day + simvastatin 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + simvastatin 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total population (combined Non-switcher + Switcher)
Number of subjects: 0
Study: 18587307

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100.000 adrenaline (control)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.30 IU felipressine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100.000 adrenaline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100.100 adrenaline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All anesthetics studied
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All anesthetics compared to lidocaine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Measurement of systolic blood pressure, diastolic blood pressure and heart rate
Number of subjects: 84
Study: 15687321

Group type: EXPERIMENTAL
Intervention: 100 mg L-000845704 once daily (qd)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 400 mg L-000845704 once daily (qd)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 200 mg L-000845704 twice daily (bid)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: All doses of L-000845704
Number of subjects: 227
Study: 11806644

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser radiation at 200 mJ
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sodium hypochloride rinsing
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser radiation at 100 mJ
Number of subjects: 114
Study: 10526807

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8725495

Group type: EXPERIMENTAL
Intervention: Neuronal cytoplasmic inclusions (NCIs) observed in the central nervous systems of patients with MSA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neuronal cytoplasmic inclusions (NCIs)
Number of subjects: 18
Study: 2025770

Group type: EXPERIMENTAL
Intervention: Compression applied at 5 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Compression applied immediately after injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Compression applied after the 5 minute film
Number of subjects: 60
Study: 6093528

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (intramuscularly or intravenously)
Number of subjects: 2635

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose of 250 mg)
Number of subjects: 2635

Group type: COMPARATOR
Intervention: Ceftriaxone (single dose)
Number of subjects: 2635
Study: 31314045

Group type: EXPERIMENTAL
Intervention: iFR-guided treatment
Number of subjects: 2492

Group type: COMPARATOR
Intervention: FFR-guided treatment
Number of subjects: 2492
Study: 29877901

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) application for improving functional vision
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no AR application)
Number of subjects: 48
Study: 27114196

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 mg or 100 mg based on efficacy and safety)
Number of subjects: 11364

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 11364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11364
Study: 25699375

Group type: COMPARATOR
Intervention: Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution (ANH) + Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60
Study: 22645995

Group type: EXPERIMENTAL
Intervention: 0.5 mg estriol as vaginal cream
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 87
Study: 20653966

Group type: EXPERIMENTAL
Intervention: Peer-led education (weekly educational programs for one month)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study: 20969443

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using an InGaAlP diode laser, emitting light at 660 nm, 40 mW, and 4 J/cm².
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no LLLT treatment).
Number of subjects: 42
Study: 15607123

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg, b.i.d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12296593

Group type: EXPERIMENTAL
Intervention: Dolder bar attachment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ball attachment
Number of subjects: 36
Study: 9725475

Group type: EXPERIMENTAL
Intervention: Slow-release amitriptyline formulation
Number of subjects: 0
Study: 8067694

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (1000 mg/m2 B.S.A. x 5 days) and Mitomycin‐C (14 mg/m2 B.S.A. 6 week intervals)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (750 mg/m2 B.S.A. x 5 days) and a‐Interferon (5 miu/m2 B.S.A. daily x 5 then 3 times a week (TIW))
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (500 mg/m2 B.S.A. x 5 days), a‐Interferon (5 miu/m2 B.S.A. x 5 days then TIW) and 13‐Cis Retinoic Acid in escalating doses daily
Number of subjects: 77
Study: 3289132

Group type: EXPERIMENTAL
Intervention: Early secondary suture combined with cefuroxime and metronidazole given intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healing by second intention
Number of subjects: 0
Study: 29733447

Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg + Allopurinol 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Verinurad and Allopurinol
Number of subjects: 0
Study: 26586860

Group type: EXPERIMENTAL
Intervention: Modified group-based vestibular rehabilitation (VR) intervention consisting of group sessions, individually modified VR exercises, a home exercise program, and an exercise diary over 8 weeks.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Modified group-based vestibular rehabilitation (VR) intervention
Number of subjects: 4
Study: 25641452

Group type: COMPARATOR
Intervention: Transrectal (TR) 14-core biopsy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transperineal (TP) 14-core biopsy
Number of subjects: 108
Study: 23653013

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (intra-muscular testosterone administered every 14 days to achieve BT levels 70-270 ng/dL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (sesame seed oil administered every 14 days)
Number of subjects: 29
Study: 20439641

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment (375 mg/m² intravenously once every 3 months)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment
Number of subjects: 465
Study: 18439225

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) exposure
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 17
Study: 16174118

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37